<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02440750</url>
  </required_header>
  <id_info>
    <org_study_id>HYSTERO</org_study_id>
    <nct_id>NCT02440750</nct_id>
  </id_info>
  <brief_title>Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cagliari</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cagliari</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The presence of a thin endometrium has an important role in allowing the best conditions for
      hysteroscopic surgery. The aim of this study is to evaluate the efficacy of a 21 day
      administration of 2 mg of dienogest versus ulipristal acetate 5 mg, in rapid endometrial
      preparation to operative hysteroscopy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endometrial thickness</measure>
    <time_frame>Change in mm from baseline after farmacological therapy</time_frame>
    <description>We perform a transvaginal ultrasound (baseline) and we measure the maximum thickness of endometrial line; at the time of surgery (operative hysteroscopy) we repeat the ultrasound after pharmacological treatment. It will be expressed in mm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ovarian follicle dimensions</measure>
    <time_frame>Change in mm from baseline after farmacological therapy</time_frame>
    <description>We perform a transvaginal ultrasound (baseline) and we measure the maximum diameter of follicles; at the time of surgery (operative hysteroscopy) we repeat the ultrasound after pharmacological treatment. It will be expressed in mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial appearance</measure>
    <time_frame>Change from baseline after farmacological therapy</time_frame>
    <description>We perform a diagnostic hysteroscopy (baseline) and we describe the endometrial appearance; at the time of surgery (operative hysteroscopy) we describe the endometrial appearance after pharmacological treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative time</measure>
    <time_frame>Within 2 hours after the end of the hysteroscopy</time_frame>
    <description>It will be expressed in minutes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>Dienogest</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women selected for operative hysteroscopy that received for 21 days dienogest 2 mg/die</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulipristal acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women selected for operative hysteroscopy that received for 21 days ulipristal acetate 5 mg/die</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>operative hysteroscopy</intervention_name>
    <description>Performed under general or local anesthesia, antibioprophylaxis may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.</description>
    <arm_group_label>Dienogest</arm_group_label>
    <arm_group_label>Ulipristal acetate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dienogest</intervention_name>
    <description>21 days administration of dienogest 2 mg/die</description>
    <arm_group_label>Dienogest</arm_group_label>
    <other_name>Visanne</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulipristal acetate</intervention_name>
    <description>21 days administration of ulipristal acetate 5 mg/die</description>
    <arm_group_label>Ulipristal acetate</arm_group_label>
    <other_name>Esmya</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis at office hysteroscopy of symptomatic submucous myomas with intramural
             development (G1 and G2)

        Exclusion Criteria:

          -  pregnancy

          -  other hormonal therapy in the previous 8 weeks

          -  hepatic or renal impairment

          -  any medical condition that would increase the surgical risk

          -  refusal or unable to sign written consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2015</study_first_submitted>
  <study_first_submitted_qc>May 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2015</study_first_posted>
  <last_update_submitted>March 8, 2016</last_update_submitted>
  <last_update_submitted_qc>March 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cagliari</investigator_affiliation>
    <investigator_full_name>Stefano Angioni</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dienogest</mesh_term>
    <mesh_term>Nandrolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

